News & Updates

Show Multimedia Only

Seladelpar improves liver outcomes in cirrhosis patients with PBC, portal hypertension

Treatment with seladelpar for 4 years yields consistent biochemical efficacy, with no new safety concerns, among patients with cirrhosis and primary biliary cholangitis (PBC), as shown by interim results from the open-label ASSURE study.

Seladelpar improves liver outcomes in cirrhosis patients with PBC, portal hypertension

14 hours ago

Pemvidutide positively IMPACTs patients with MASH

20 Jun 2026 by

Treatment with pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist, led to significant improvements in primary noninvasive tests (NITs), such as Enhanced Liver Fibrosis (ELF) and Liver Stiffness Measurement (LSM), and weight loss in patients with metabolic dysfunction-associated steatohepatitis (MASH), according to the phase IIb IMPACT trial presented at EASL 2026.

Pemvidutide positively IMPACTs patients with MASH

20 Jun 2026

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

19 Jun 2026 by

In a post hoc analysis of the phase III MAESTRO-NASH trial presented at ADA 2026, systemic thyroid function remained stable with resmetirom, supporting its extrahepatic safety in individuals with metabolic dysfunction-associated steatohepatitis (MASH).

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

19 Jun 2026

VISTAS: Volixibat alleviates cholestatic itch in PSC

16 Jun 2026 by

The investigational ileal bile acid transporter (IBAT) inhibitor volixibat provides rapid and sustained improvement in pruritus in patients with primary sclerosing cholangitis, according to the topline results of the VISTAS study.

VISTAS: Volixibat alleviates cholestatic itch in PSC

16 Jun 2026

FMT reduces alcohol cravings, relapse rates in patients with ALD

16 Jun 2026 by

Faecal microbiota transplantation (FMT) significantly improves alcohol abstinence and reduces relapse episodes for up to 6 months in patients with alcohol-related liver disease (ALD) and alcohol use disorder (AUD), as shown in a recent study presented at EASL 2026.

FMT reduces alcohol cravings, relapse rates in patients with ALD

16 Jun 2026

Procalcitonin a novel tumour biomarker for diagnosis, disease monitoring in FLC

15 Jun 2026

A recent study has found procalcitonin to be a sensitive and specific serum biomarker for fibrolamellar carcinoma (FLC), making it a potential target for diagnosis and monitoring of treatment response.

Procalcitonin a novel tumour biomarker for diagnosis, disease monitoring in FLC

15 Jun 2026

Alcohol abstinence enables recompensation, prolongs survival in cirrhosis

15 Jun 2026 by

Patients with decompensated alcohol-related cirrhosis who abstained from alcoholic drinking achieve recompensation, which is associated with survival benefits when abstinence is sustained, reveals a study.

Alcohol abstinence enables recompensation, prolongs survival in cirrhosis

15 Jun 2026

Adjuvant atezolizumab plus bevacizumab falls short of improving RFS in high-risk HCC

15 Jun 2026

An updated analysis of the IMbrave050 study reveals no sustained benefit on recurrence-free survival (RFS) among patients with high-risk hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab. Moreover, data on overall survival (OS) remains incomplete.

Adjuvant atezolizumab plus bevacizumab falls short of improving RFS in high-risk HCC

15 Jun 2026

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

12 Jun 2026 by

In the treatment of patients with unresectable embolization-eligible hepatocellular carcinoma (eeHCC), combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab regular interval durvalumab) regimen with or without lenvatinib substantially increases progression-free survival (PFS), as shown in the global phase 3 EMERALD-3 study.

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

12 Jun 2026

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

10 Jun 2026 by

The novel antisense oligonucleotide bepirovirsen has induced functional cure in one-fifth of patients with chronic hepatitis B virus (HBV) infection in the phase 3 B-Well 1 and B-Well 2 trials.

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

10 Jun 2026

News & Updates

Showing Hepatology articles

Showing

Specialty:

Seladelpar improves liver outcomes in cirrhosis patients with PBC, portal hypertension

Seladelpar improves liver outcomes in cirrhosis patients with PBC, portal hypertension

Pemvidutide positively IMPACTs patients with MASH

Pemvidutide positively IMPACTs patients with MASH

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

VISTAS: Volixibat alleviates cholestatic itch in PSC

VISTAS: Volixibat alleviates cholestatic itch in PSC

FMT reduces alcohol cravings, relapse rates in patients with ALD

FMT reduces alcohol cravings, relapse rates in patients with ALD

Procalcitonin a novel tumour biomarker for diagnosis, disease monitoring in FLC

Procalcitonin a novel tumour biomarker for diagnosis, disease monitoring in FLC

Alcohol abstinence enables recompensation, prolongs survival in cirrhosis

Alcohol abstinence enables recompensation, prolongs survival in cirrhosis

Adjuvant atezolizumab plus bevacizumab falls short of improving RFS in high-risk HCC

Adjuvant atezolizumab plus bevacizumab falls short of improving RFS in high-risk HCC

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen